Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 1
1996 1
1998 1
1999 2
2000 2
2002 1
2004 1
2005 1
2012 3
2013 7
2014 5
2015 5
2016 9
2017 9
2018 9
2019 10
2020 10
Text availability
Article attribute
Article type
Publication date

Search Results

72 results
Results by year
Filters applied: . Clear all
Page 1
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Strosberg J, et al. Among authors: Kulkarni HR. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427. N Engl J Med. 2017. PMID: 28076709 Free PMC article. Clinical Trial.
German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.
Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A, Bartenstein P, Pfestroff A, Luster M, Lützen U, Marx M, Prasad V, Brenner W, Heinzel A, Mottaghy FM, Ruf J, Meyer PT, Heuschkel M, Eveslage M, Bögemann M, Fendler WP, Krause BJ. Rahbar K, et al. Among authors: Kulkarni HR. J Nucl Med. 2017 Jan;58(1):85-90. doi: 10.2967/jnumed.116.183194. Epub 2016 Oct 20. J Nucl Med. 2017. PMID: 27765862 Free article. Clinical Trial.
177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer.
von Eyben FE, Singh A, Zhang J, Nipsch K, Meyrick D, Lenzo N, Kairemo K, Joensuu T, Virgolini I, Soydal C, Kulkarni HR, Baum RP. von Eyben FE, et al. Among authors: Kulkarni HR. Oncotarget. 2019 Mar 29;10(25):2451-2461. doi: 10.18632/oncotarget.26789. eCollection 2019 Mar 29. Oncotarget. 2019. PMID: 31069008 Free PMC article.
177Lu-3BP-227 for Neurotensin Receptor 1-Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results.
Baum RP, Singh A, Schuchardt C, Kulkarni HR, Klette I, Wiessalla S, Osterkamp F, Reineke U, Smerling C. Baum RP, et al. Among authors: Kulkarni HR. J Nucl Med. 2018 May;59(5):809-814. doi: 10.2967/jnumed.117.193847. Epub 2017 Oct 12. J Nucl Med. 2018. PMID: 29025990 Free article.
68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, Kulkarni HR, Lassmann M, Klette I, Eiber M, Schwaiger M, Wester HJ. Weineisen M, et al. Among authors: Kulkarni HR. J Nucl Med. 2015 Aug;56(8):1169-76. doi: 10.2967/jnumed.115.158550. Epub 2015 Jun 18. J Nucl Med. 2015. PMID: 26089548 Free article.
177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, Schottelius M, Mueller D, Klette I, Wester HJ. Baum RP, et al. Among authors: Kulkarni HR. J Nucl Med. 2016 Jul;57(7):1006-13. doi: 10.2967/jnumed.115.168443. Epub 2016 Jan 21. J Nucl Med. 2016. PMID: 26795286 Free article.
From Bench to Bedside-The Bad Berka Experience With First-in-Human Studies.
Zhang J, Singh A, Kulkarni HR, Schuchardt C, Müller D, Wester HJ, Maina T, Rösch F, van der Meulen NP, Müller C, Mäcke H, Baum RP. Zhang J, et al. Among authors: Kulkarni HR. Semin Nucl Med. 2019 Sep;49(5):422-437. doi: 10.1053/j.semnuclmed.2019.06.002. Epub 2019 Jul 6. Semin Nucl Med. 2019. PMID: 31470935 Review.
72 results
Jump to page
Feedback